Nasal spray vaccine against COVID-19 enters early human testing
NCT ID NCT07416539
First seen Feb 19, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This early-stage trial tests two versions of a nasal spray vaccine called COV2, designed to protect against COVID-19. About 20 healthy adults who have already had at least two COVID-19 shots will receive two doses of the nasal vaccine. The study checks for side effects and measures how well the vaccine boosts the immune system against the Omicron BA.5 variant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kuopio University Hospital, ENT policlinic
RECRUITINGKuopio, Northern Savonia, 70210, Finland
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.